The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 04, 2017

Filed:

Sep. 12, 2012
Applicants:

Timothy Cardozo, New York, NY (US);

Xiangpeng Kong, New York, NY (US);

Susan Zolla-pazner, New York, NY (US);

Inventors:

Timothy Cardozo, New York, NY (US);

Xiangpeng Kong, New York, NY (US);

Susan Zolla-Pazner, New York, NY (US);

Assignee:

New York University, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/64 (2006.01); A61K 38/19 (2006.01); A61K 39/21 (2006.01); A61K 39/12 (2006.01); C07K 7/08 (2006.01); C07K 14/005 (2006.01); C07K 14/245 (2006.01); C07K 16/10 (2006.01); C07K 14/28 (2006.01); G01N 33/68 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 38/19 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); C07K 7/64 (2013.01); C07K 14/005 (2013.01); C07K 14/245 (2013.01); C07K 14/28 (2013.01); C07K 16/1063 (2013.01); G01N 33/56988 (2013.01); G01N 33/6854 (2013.01); A61K 2039/545 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/64 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2319/55 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); C12N 2799/023 (2013.01); G01N 2333/162 (2013.01); G01N 2469/20 (2013.01);
Abstract

The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.


Find Patent Forward Citations

Loading…